Coyne Terrance P. 4

What Happened
Terrance P. Coyne, Executive Vice President & Chief Financial Officer of Royalty Pharma plc (RPRX), received 26,626 Class A ordinary shares on February 11, 2026 as the settlement of Equity Performance Awards. The shares were granted at $0.00 per share (total cash paid $0), and the Form 4 records the acquisition as an award/grant (transaction code A).

Key Details

• Transaction date: 2026-02-11; form filed 2026-02-13 (timely within the typical two-business-day window).
• Shares acquired: 26,626 Class A ordinary shares; price per share: $0.00; total cash paid: $0.
• Footnote: Acquisition exempt under Rule 16b-3 in connection with settlement of Equity Performance Awards (per filing footnote F1).
• Shares owned after transaction: not specified as a single direct total on the Form 4; filing notes additional indirect/exchangeable interests (see Context).
• Filing appears timely (no late-report indication).

Context
This was a compensation-related equity award (settlement of performance-based awards), not an open-market purchase—such awards are routine for executives and reflect company compensation, not direct market buying or selling. The filing also notes that the reporting person and related family vehicles hold limited partnership interests exchangeable into 6,448,180 Class A shares and Class E shares of RPH exchangeable into 1,807,277 Class A shares; the Class E shares are subject to vesting conditions and are not necessarily immediately convertible.